Evinacumab in Patients with Refractory Hypercholesterolemia

Evinacumab in Patients with Refractory Hypercholesterolemia

Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-12, Vol.383 (24), p.2307-2319
Hauptverfasser: Rosenson, Robert S, Burgess, Lesley J, Ebenbichler, Christoph F, Baum, Seth J, Stroes, Erik S.G, Ali, Shazia, Khilla, Nagwa, Hamlin, Robert, Pordy, Robert, Dong, Yuping, Son, Vladimir, Gaudet, Daniel
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Angiopoietin
Angiopoietin-like Proteins - antagonists & inhibitors
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Arteriosclerosis
Body weight
Cardiology
Cardiovascular disease
Cholesterol
Cholesterol, LDL - blood
Coronary vessels
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Female
Humans
Hypercholesterolemia
Hyperlipoproteinemia Type II - drug therapy
Infusions, Intravenous
Injections, Subcutaneous
Intravenous administration
Lipids
Low density lipoprotein
Male
Middle Aged
Monoclonal antibodies
Mutation
Statins
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2031049